Search results
Results from the WOW.Com Content Network
Iodine-131 (131 I, I-131) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. [3] It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production.
131 I or I131: iodine-131 (aka radioactive iodine or radioiodine) IA: intra-arterial: intra-articular: IAA: insulin autoantibody IABP: intra-aortic balloon pump: IAI: intra-amniotic infection: IBC: inflammatory breast cancer: IBD: inflammatory bowel disease: IBS: irritable bowel syndrome: IC: ileocecal: immunocompromised: informed consent ...
Product labeling for diagnostic 131 I iobenguane recommends giving potassium iodide one day before injection and continuing 5 to 7 days following. [ 19 ] 131 I iobenguane used for therapeutic purposes requires a different pre-medication duration, beginning 24–48 hours before iobenguane injection and continuing 10–15 days after injection.
The beta particles emitted by the radioisotope destroys the associated thyroid tissue with little damage to surrounding tissues (more than 2.0 mm from the tissues absorbing the iodine). Due to similar destruction, 131 I is the iodine radioisotope used in other water-soluble iodine-labeled radiopharmaceuticals (such as MIBG) used therapeutically ...
[1] [2] When the iodine atom is a radioactive isotope (iodine-125 or iodine-131), it is used as an adrenal cortex radiotracer in the diagnosis of patients suspected of having Cushing's syndrome, hyperaldosteronism, [3] pheochromocytoma, and adrenal remnants following total adrenalectomy. [1] [2]
Iodine-131 (131 I) is the most common RNT worldwide and uses the simple compound sodium iodide with a radioactive isotope of iodine. The patient (human or animal) may ingest an oral solid or liquid amount or receive an intravenous injection of a solution of the compound. The iodide ion is selectively taken up by the thyroid gland.
The patient swallows a radioisotope of iodine in the form of capsule or fluid, and the absorption (uptake) of this radiotracer by the thyroid is studied after 4–6 hours and after 24 hours with the aid of a scintillation counter. The dose is typically 0.15–0.37 MBq (4–10 μCi) of 131 I iodide, or 3.7–7.4 MBq (100–200 μCi) of 123 I ...
Iodine-131 (usually as iodide) is a component of nuclear fallout, and is particularly dangerous owing to the thyroid gland's propensity to concentrate ingested iodine and retain it for periods longer than this isotope's radiological half-life of eight days. For this reason, people at risk of exposure to environmental radioactive iodine (iodine ...